Sagimet Biosciences, a clinical-stage biopharmaceutical company, has been added to the Russell 2000 and Russell 3000 indexes as of June 29, 2026. This inclusion reflects the company's growth and progress, particularly as it plans to start a Phase 3 clinical trial for its acne drug denifanstat later this year. If approved, denifanstat would be the first new oral acne treatment in over 40 years for patients aged 12 and older. The company has secured funding through 2028 to support its clinical programs and anticipates increased visibility from being part of these indexes.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Blackrock CEO Larry Fink expressed strong optimism about market prospects over the next year, citing technology-driven productivity and margin expansion as key growth drivers. He noted that overall financial leverage is much lower than during the 200...
Velvet token fell about 18% in one day amid heavy selling, yet it remains the top gainer among the top 100 tokens with a 571% increase over the past 90 days. Despite $24 million exiting its perpetual Futures market in two weeks, bullish sentiment per...
